Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Spectral Medical Inc > Ten 2 go …!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(316)
•••
Comment by hmmmmmmmmon Jan 07, 2025 12:06pm
115 Views
Post# 36392550

RE:RE:RE:RE:RE:RE:Ten 2 go …!

RE:RE:RE:RE:RE:RE:Ten 2 go …!My issue is management has a responsability to inform investors of material information. Like necessary trial enrollment.

It's not a big ask, this is 101 stuff.

If they have been told- your trial now needs 159 patients for the FDA to see it as final- investors need to be informed of that both timely and clearly.

None of us know what this trial needs to be fully enrolled.  Normal?

Also, if they counted 6 patients- but those patients were rejected by some oversight- that information should also be defined for investors.

Kellum spent more time talking about the maternity leave of someone we don't know- than important investor information.

I agree that this may just be a time and money set back, but management doesn't get to decide to hold back basic material info. And as we've seen with this group in the past they would rather run from bad news than be forthright. (Dialco)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities